FindTrial
Sign In

50 mg etanercept

DRUG3 trials

Sponsors

Amgen, Eli Lilly and Company

Conditions

PsoriasisRheumatoid Arthritis

Phase 3

Enbrel Liquid Immunogenicity Protocol
CompletedNCT00249041
AmgenRheumatoid Arthritis
Start: 2005-10-31End: 2007-03-31Updated: 2010-07-30
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
CompletedNCT01597245
Eli Lilly and CompanyPsoriasis
Start: 2012-05-18End: 2019-06-18Updated: 2020-06-26
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
CompletedNCT01646177
Eli Lilly and CompanyPsoriasis
Start: 2012-07-28End: 2019-07-22Updated: 2020-07-28

Related Papers

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60
Dermatology and Therapy2024-04-014 citations
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
2024-03-233 citations
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
2023-07-036 citations
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
2022-03-139 citations
Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool.
2021-05-2813 citations
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.
2020-11-2846 citations
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
Journal of Drugs in Dermatology2020-07-014 citations
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
2020-03-2144 citations
Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab
Journal of the American Academy of Dermatology2020-02-211 citations
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
2018-11-2111 citations
Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis
Journal of Investigative Dermatology2018-05-0852 citations
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
2017-04-0128 citations
Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of <scp>UNCOVER</scp>‐3
Journal of the European Academy of Dermatology and Venereology2016-11-0582 citations
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
New England Journal of Medicine2016-06-08818 citations
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis
JAMA Dermatology2016-03-0852 citations
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
2015-06-10601 citations